Serum 25-Hydroxyvitamin D level in Restless Legs Syndrome: A controlled study
Betül Çiftçi¹*, Sacide Nur Saracgil Coşar², Aslıhan Uzunkulaoğlu³

1 Department of Physiotherapy and Rehabilitation, Kırklareli University Faculty of Health Science, Kırklareli, TR
2 Department of Physical Medicine and Rehabilitation, Başkent University Faculty of Medicine, Ankara, TR
3 Department of Physical Medicine and Rehabilitation, Ufuk University Faculty of Medicine, Ankara, TR

* Corresponding Author: Betül Çiftçi E-mail: btlcftc@hotmail.com

ABSTRACT

Objective: We aimed to investigate 25-hydroxyvitamin D (25-OHD) level on a group of restless legs syndrome (RLS) patients.

Material and Methods: Twenty-one RLS patients and fourteen age and gender healthy controls (non RLS) with similar age and gender were included in the study. All patients underwent a physical examination for the neurologic and musculoskeletal system. The 25-OHD level was measured for all participants.

Results: The 25-hydroxyvitamin D levels were higher in the RLS patient group (20.06±8.79 ng/ml) than in the healthy control group (14.75±4.67 ng/ml). In the healthy control group ‘without the RLS syndrome’, 25-hydroxyvitamin D levels were below the normal range (<20 ng/ml). However, there were no statistical differences in terms of vitamin D level between the RLS and Control groups (p>0.05).

Conclusion: In this study, due to the absence of RLS syndrome in the control group despite low 25-hydroxyvitamin D levels (<20 ng/ml), a relationship could not be established between 25-hydroxyvitamin D levels and RLS syndrome. The cause of RLS syndrome does not seem to depend on a single parameter such as 25-OHD level.

Keywords: Movement Disorder; Restless Legs Syndrome; 25-hydroxyvitamin D

INTRODUCTION

Restless legs syndrome (RLS) is also known as Willis-Ekbom disease (WED) and a neurological movement disorder characterized by the urge to move legs due to uncomfortable and unpleasant sensations in the legs (1). The RLS syndrome was first described by Thomas Willis in 1685. It is Ekbom, which in 1945 defined all the clinical features of the syndrome and named "restless leg syndrome" (2). Because of the cognitions of these pioneers, the nonprofit Restless Legs Syndrome Foundation’s name was changed as the Willis -Ekbom Disease Foundation (3). The diagnosis RLS based on 2012 revised International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria. All the essential criterias for RLS are: 1- The urge to move legs due to feelings of uncomfortable and unpleasant sensation 2- The urge to move legs and feelings of uncomfortable and unpleasant sensation begin or worsen during periods of rest or inactivity such as lying down or sitting 3- The urge to move the legs and unpleasant sensations partially or totally relieved by movement such as walking or stretching 4- The urge to move and unpleasant sensations that occur during rest or inaction; occurs only in the evening or at night or gets worse at this time 5- The above features are not caused by other medical or behavioural conditions such as arthritis, leg cramps, myalgia, venous stasis, leg oedema. (4). Primary RLS is associated with genetic factors that disrupt the brain's iron metabolism, dopaminergic system dysfunction (5). In some studies, it has been reported that vitamin D is the protector of dopaminergic neurons in the nigrostriatal region. Also, vitamin D deficiency is associated with neuropsychiatric diseases such as dementia, multiple sclerosis (MS), parkinsonism (6,7).

There are few studies reporting the relationship between vitamin D and RLS. In this study, we aimed to investigate the 25-hydroxyvitamin D (25-OHD) level of RLS patients and paired control group to evaluate the relationship between 25-OHD level and RLS.
MATERIAL and METHODS

The study protocol was approved by the Institutional Review Board of the Başkent University ethics committee (protocol number: KA12/222, date: 12/12/2012). The Declaration of Helsinki protocols were followed. All participants were informed about the study and signed written informed consent before interventions.

Twenty-one RLS patients and fourteen healthy volunteers were included to study. Age and gender healthy controls with similar age and gender were selected. Determination of RLS was based on the 2012 revised International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria (8, 9). All RLS patients did not receive any medical treatment related to this diagnosis.

Patients with severe liver and kidney failure, severe neurologic disorder, polyneuropathy, diabetes mellitus, vitamin B12 deficiency, iron and ferritin deficiency, uncontrolled hypo/hyperthyroidism were excluded. The age distribution of all participants was in the range of 18-70. All patients were examined for any musculoskeletal or other disease that can cause pain. All patients underwent a physical examination for musculoskeletal and neurological systems.

Serum 25-OHD levels of all participants were measured using Shimadzu Prominence high performance liquid chromatography (HPLC) (Shimadzu Scientific Instruments, Kyoto, Japan). According to the recommendations of the US Endocrine Society; 25-OHD <20 ng/ml (50 nmol/l) levels vitamin D deficiency; values between 21 and 29 ng / ml (between 52.5 and 72.5 nmol) were defined as vitamin D insufficiency and 25-OHD level> 30 ng/ml (75 nmol/l) as the optimal level (10).

The means and standard deviations were given as descriptive statistics. All data for normality was tested by using Kolmogorov-Smirnov test. To compare the differences between two groups, Mann Whitney U was used. A level of significance of p<0.05 was accepted. All analyses were performed using the SPSS for Windows 18.0 software program.

RESULTS

Of the 35 participants included in the study, Group 1 (n = 21) constituted the RLS group, while Group 2 (n = 14) was the healthy control group (non RLS group). The demographic characteristics and 25-OHD levels of the patients and healthy controls are presented in Table 1.

While there was a statistically significant difference between the groups in terms of age (p <0.05), there was no difference in gender (p> 0.05). 25-OHD levels were higher in the RLS group than in the control group. There was no difference in 25-OHD levels between the groups (p> 0.05) Table 1.

DISCUSSION

In our study high 25-OHD level was found in RLS patients but there were no significant differences between groups. Restless legs syndrome (RLS), is a common neurological, sensorimotor disorder manifested by an urge or a need to move the limbs to stop unpleasant sensations in the evening or while at rest (1, 11-14). Most of RLS cases appear by idiopathic origin (5). The pathophysiology of RLS is not known precisely but genetic factors, iron deficiency and the dopaminergic system may be a role in RLS. Genetic factor is also important for the pathophysiology of RLS. In a study, it was reported that 63% of patients had first degree kinship (15). Secondary RLS may be caused by underlying medical conditions such as iron deficiency anaemia, renal failure, and pregnancy (5).

In some studies, it is stated that iron deficiency or irregularity is the most important mechanism for understanding the pathophysiology of RLS. Circadian changes in brain iron status appear to be important for RLS (16). Tyrosine hydroxylase is an important enzyme for dopamine synthesis and it uses iron as a cofactor. Therefore, RLS becomes a sensorimotor dysfunction (12-14).

Vitamin D is a fat-soluble prohormone nutrient that has skeletal and extra-skeletal functions. In some studies, lower vitamin D status was found in association with neuropsychiatric diseases such as dementia, MS, bipolar disorders (6, 7). Also, vitamin D has an essential function for the dopaminergic system; it regulates nervous system function (17). In human and rat substantia nigra, tyrosine hydroxylase positive neurons have a vitamin D receptor in the nucleus (18).

It has been reported that 1-alpha, 25- (OH) (2) D (3) reduces oxidative stress and therefore plays a role in protecting dopaminergic neurons against cytotoxicity caused by glutamate and dopaminergic toxins (19). RLS relation with the dopaminergic system; and due to the relationship between dopaminergic neurons and vitamin D, we investigated 25-OHD in a group of restless leg syndrome (RLS) patients. We found that, there was no statistically significant difference between the groups in terms of 25-OHD levels. However, there are several studies in the literature showing the relationship between RLS and 25-OHD levels (20-22).

In some studies, the mean of 25-OHD was showed significantly lower in the elderly persons (23-25). In this study, the median age of the control group was higher than the patient group, but the 25-OHD level was lower in the control group than the patient group. The age effect may be the reason for this result.

Table 1. Demographic characteristics of the patient and control groups

| Variables                  | RLS Patient Group (n=21) mean ± SD | non-RLS Control Group (n=14) mean ± SD | p value |
|----------------------------|-----------------------------------|--------------------------------------|---------|
| Age (year)                 | 49.05±14.38                      | 57.14±9.84                          | 0.000   |
| Sex (Female/Male)          | 15/6                              | 11/3                                 | 0.200   |
| 25 hydroxyvitamin D (ng/ml)| 20.06±8.79                       | 14.75±4.67                          | 0.062   |

*p<0.05, meanSD; mean=standard deviation
It is known that vitamin D levels change according to the season. Lower vitamin D deficiency in a study conducted in Turkey were found to be at a higher rate (26). The inability to evaluate the seasonal variation of the 25-OH D level of the participants is one of the limitations of our study. In addition, our sample size may have limited our ability to detect differences between groups.

**CONCLUSION**

We did not find a significant difference between the RLS group and the control group in terms of 25-OH D levels. The cause of RLS syndrome does not seem to depend on a single parameter such as 25-OH D level. Prospective studies with larger sample groups and seasonal changes are also needed.

**Acknowledgment:** None

**Author Contributions:** BC, SNSC, AU: Concept, Data collection and/or processing, Analysis and/or interpretation, Literature review, BC: Writing, Revision.

**Conflict of interest:** The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. This research did not receive and a specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Ethical approval:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by Local Ethical Committee. All procedures performed in studies with human participants met the ethical standards of the Institutional Research Commission and the 1964 Declaration of Helsinki and its subsequent amendments or comparable ethical standards.

**REFERENCES**

1. Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population survey. Arch Intern Med. 2005;165(11):1286-1292. doi:10.1001/archinte.165.11.1286

2. Coccagna G, Vetrugno R, Lombardi C, Provini F. Restless legs syndrome: an historical note. Sleep Med. 2004;5(3):279-283. doi:10.1016/j.sleep.2004.01.002

3. Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG. Medical Advisory Board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88(9):977-986. doi:10.1016/j.mayocp.2013.06.016

4. Rana AQ, Khan F, Mosabhir A, Ondo W. Differentiating nocturnal leg cramps and restless legs syndrome. Expert Rev Neurother. 2014;14(7):813-818. doi:10.1586/14737175.2014.927734

5. Nagandla K, De S. Restless legs syndrome: pathophysiology and modern management. Postgrad Med J. 2013;89(1053):402-410. doi:10.1136/postgradmedj-2012-131634.

6. Cherнак GP, Troen BR, Florez HJ, Ros BA, Levis S. Some new food for thought: the role of vitamin D in the mental health of older adults. Curr Psychiatry Rep. 2009;11(1):12-19. doi:10.1007/s11920-009-0003-3

7. Wang JY, Wu JN, Cheng TL, Hoffer BJ, Chen HH, Borlongan CV, et al. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 2001;904(1):67-75. doi:10.1016/s0006-8993(01)02450-7

8. http://irlssg.org/diagnostic-criteria/; 2012

9. Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelmann JW, et al. Restless legs syndrome/Wells-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleep Med. 2014;15(8):860-873. doi:10.1016/j.sleep.2014.03.025

10. Romagnoli E, Pepe J, Piemonte S, Cipriani C, Minnissi S. Management of endocrine disease: value and limitations of assessing vitamin D nutritional status and advised levels of vitamin D supplementation. Eur J Endocrinol. 2013;169(4):R59-R69. doi:10.1530/EJE-13-0435.

11. Rye DB, Trott LM. Restless legs syndrome and periodic leg movements of sleep. Neurol Clin. 2012;30(4):1137-1166. doi:10.1016/j.ncl.2012.08.004

12. Rizzo V, Aricò I, Liotta G, Ricciardi L, Mastroeni C, Morgante F, et al. Impairment of sensory-motor integration in patients affected by RLS. J Neurol. 2010;257(12):1979-1985. doi:10.1007/s00415-010-5644-y

13. Patel N, Jankovic J, Halliet M. Sensory aspects of movement disorders. Lancet Neurol. 2014;13(1):100-112. doi:10.1016/s1474-4423(13)70213-8

14. Ku J, Cho YW, Lee YS, Moon HI, Chang H, Earley CJ, et al. Functional connectivity alteration of the thalamus in restless legs syndrome patients during the asymptomatic period: a resting-state connectivity study using functional magnetic resonance imaging. Sleep Med. 2014;15(3):289-294. doi:10.1016/j.sleep.2013.09.030

15. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapière O, Lespérance F. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12(1):61-65. doi:10.1002/mds.870120111

16. Earley CJ, Connor JR, Beard JL, Clardy SL, Allen RP. Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. Sleep. 2005;28(9):1069-1075. doi:10.1093/sleep/28.9.1069

17. Wrzeszek M, Łukaszewicz J, Wrzeszek M, Jakubczyk M, Matsumoto H, Piątkiewicz P, et al. Vitamin D and the central nervous system. Pharmacol Rep. 2013;65(2):271-278. doi:10.1523/PRP8.015012.0101613

18. Cui X, Pelekanos M, Liu PY, Burne TH, McGrath JJ, Eyles DW. The vitamin D receptor in dopamine neurons; its presence in human substantia nigra and its ontogenesis in rat midbrain. Neuroscience. 2013;236:77-87. doi:10.1016/j.neuroscience.2013.01.035

19. Ibi M, Sawada H, Nakamichi K, Tatsuaki H, Kaneko S, et al. Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology. 2001;40(6):761-771. doi:10.1016/S0028-3908(01)00009-0

20. Oran M, Unsal C, Albayrak Y, Tulhaba F, Oguz K, Avci O, et al. Possible association between vitamin D deficiency and restless legs syndrome. Neuropsychiatr Dis Treat. 2014;10:953-958. Published 2014 May 21. doi:10.2147/NDT.S63599

21. Çakar T, Doğan G, Subaşi V, Filiz MB, Ulker N, Doğan ŞK, et al. An evaluation of sleep quality and the prevalence of restless leg syndrome in vitamin D deficiency. Acta Neurol Belg. 2015;115(4):623-627. doi:10.1007/s13760-015-0474-4

22. Balaban H, Yildiz ÖK, Çiğ G, Şentürk IA, Erselcan T, Bolayır E, et al. Serum 25-hydroxyvitamin D levels in restless legs syndrome patients. Sleep Med. 2012;13(7):953-957. doi:10.1016/j.sleep.2012.04.009

23. Stamp TC, Round JM. Seasonal changes in human plasma levels of 25-hydroxyvitamin D. Nature. 1974;247(542):563-565. doi:10.1038/247656a0
24. Lester E, Skinner RK, Wills MR. Seasonal variation in serum-25-hydroxyvitamin-D in the elderly in Britain. Lancet. 1977;1(8019):979-980. doi:10.1016/s0140-6736(77)92280-2

25. Schramm S, Lahner H, Jöckel KH, Erbel R, Führer D, Moebus S; Heinz Nixdorf Recall Study Group. Impact of season and different vitamin D thresholds on prevalence of vitamin D deficiency in epidemiological cohorts—a note of caution. Endocrine. 2017;56(3):658-666. doi:10.1007/s12020-017-1292-7

26. Cinar N, Harmanci A, Yildiz BO, Bayraktar M. Vitamin D status and seasonal changes in plasma concentrations of 25-hydroxyvitamin D in office workers in Ankara, Turkey. Eur J Intern Med. 2014;25(2):197-201. doi:10.1016/j.ejim.2013.11.004
Medical Science and Discovery (http://www.medscidiscovery.com) is an international open access, peer-reviewed scientific research journal that provides rapid publication of articles in all disciplines of human health, clinical and basic medical sciences such as Biophysics, Biochemistry, Histology, Physiology, Genetics, Pathology, Toxicology, Anatomical Sciences, Pharmacology, Embryology, Internal and Surgical Medicine.

The policy of top priority of MSD is to put forward and highlight medical innovations and inspiring patents.

MSD offers an exceptionally fast publication schedule including prompt peer-review by the experts in the field and immediate publication upon acceptance. The editorial board aims at reviewing the submitted articles as fast as possible and promptly including them in the forthcoming issues. This journal is published under ethical publishing policy of international scientific Bioethics and publication rules.

MSD supports the Open Access Initiative. Abstracts and full texts (HTML and PDF format) of all articles published by MSD are freely accessible to everyone immediately upon publication.

Indexed Databases: Chemical Abstracts (CAS), Index Copernicus, Open Air, ULRICHS Database, ProQuest, Advanced Science Index, Turkish Citation Index, Research Bible, Scholar Google, NLM Catalog